Prevalence of oral manifestations in patients with HIV/AIDS
DOI:
https://doi.org/10.35381/s.v.v6i1.1747Keywords:
AIDS serodiagnosis, HIV antibodies, HIV antigens. (Source, DeCS).Abstract
Objective: To know the prevalence of oral manifestations in patients with HIV/AIDS in a national and international context, since this pathology presents a constant growth, in spite of prevention and promotion through the years by different world organizations. Method: bibliographic review. Results: 15 articles have been included, which are congruent with the objective set. Conclusion: Knowledge of the clinical picture of patients with HIV/AIDS and the behavior of the different lesions that may occur, especially oral manifestations, and the treatment plan, should be fundamental for a health professional and even more so for a dentist, since it is in the oral cavity where pathognomonic signs of this epidemic appear.
Downloads
References
Hassan AS, Pybus OG, Sanders EJ, Albert J, Esbjörnsson J. Defining HIV-1 transmission clusters based on sequence data. AIDS. 2017;31(9):1211-1222. doi:10.1097/QAD.0000000000001470
Oster AM, France AM, Panneer N, et al. Identifying Clusters of Recent and Rapid HIV Transmission Through Analysis of Molecular Surveillance Data. J Acquir Immune Defic Syndr. 2018;79(5):543-550. doi:10.1097/QAI.0000000000001856
Lamotte J. Infección por VIH/sida en el mundo actua. [Online].; 2014 [cited 2021 1 5.
Villasís Keever Angelina. A 20 años del descubrimiento del VIH [20 years after the discovery of HIV]. Rev. invest. clín. [revista en la Internet]. 2004; 56(2): 122-123.
Gulick RM, Flexner C. Long-Acting HIV Drugs for Treatment and Prevention. Annu Rev Med. 2019;70:137-150. doi:10.1146/annurev-med-041217-013717
Van Vaerenbergh K. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Verh K Acad Geneeskd Belg. 2001;63(5):447-473.
Abati S, Bramati C, Bondi S, Lissoni A, Trimarchi M. Oral Cancer and Precancer: A Narrative Review on the Relevance of Early Diagnosis. Int J Environ Res Public Health. 2020;17(24):9160. Published 2020 Dec 8. doi:10.3390/ijerph17249160
Katzenstein TL. Molecular biological assessment methods and understanding the course of the HIV infection. APMIS Suppl. 2003;(114):1-37.
Bhatt P, Manjunath M, Khakhla D, Gubrellay P, Bhargava R, Guruprasad L. Evaluación y correlación entre la estadificación funcional e histológica de la fibrosis submucosa oral: un estudio clínico-histopatológico. Natl J Maxillofac Surg . 2019;10(1):27-32. doi:10.4103/njms.NJMS_15_18
Rojas-Celis V, Valiente-Echeverría F, Soto-Rifo R, Toro-Ascuy D. New Challenges of HIV-1 Infection: How HIV-1 Attacks and Resides in the Central Nervous System. Cells. 2019;8(10):1245. Published 2019 Oct 13. doi:10.3390/cells8101245
Ranganathan K, Umadevi M, Saraswathi TR, Kumarasamy N, Solomon S, Johnson N. Oral lesions and conditions associated with human immunodeficiency virus infection in 1000 South Indian patients. Ann Acad Med Singap. 2004;33(4 Suppl):37-42.
Ranganathan K, Reddy BV, Kumarasamy N, Solomon S, Viswanathan R, Johnson NW. Oral lesions and conditions associated with human immunodeficiency virus infection in 300 south Indian patients. Oral Dis. 2000;6(3):152-157. doi:10.1111/j.1601-0825.2000.tb00326.x
Ranganathan K, Geethalakshmi E, Krishna Mohan Rao U, Vidya KM, Kumarasamy N, Solomon S. Orofacial and systemic manifestations in 212 paediatric HIV patients from Chennai, South India. Int J Paediatr Dent. 2010;20(4):276-282. doi:10.1111/j.1365-263X.2010.01050.x
Puronen CE, Ford ES, Uldrick TS. Immunotherapy in People With HIV and Cancer. Front Immunol. 2019;10:2060. Published 2019 Aug 28. doi:10.3389/fimmu.2019.02060
Adashek JJ, Junior PNA, Galanina N, Kurzrock R. Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer. J Immunother Cancer. 2019;7(1):130. Published 2019 May 22. doi:10.1186/s40425-019-0618-9
Published
How to Cite
Issue
Section
License
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
OAI-PMH: https://fundacionkoinonia.com.ve/ojs/index.php/saludyvida/oai.
